What are the causes of pneumonitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Causes of Pneumonitis

Pneumonitis is defined as focal or diffuse inflammation of the lung parenchyma that can be caused by various agents including drugs, environmental exposures, immune checkpoint inhibitors, and other factors. 1

Immune Checkpoint Inhibitor-Related Pneumonitis

  • Immune checkpoint inhibitors (ICIs) can cause pneumonitis with an overall incidence of <5% for monotherapy, with higher rates (up to 10%) reported with combination therapies 2
  • PD-1 inhibitors have higher incidence of pneumonitis (3.6%) compared to PD-L1 inhibitors (1.3%) 2
  • Radiographic patterns include cryptogenic organizing pneumonia (COP), nonspecific interstitial pneumonitis (NSIP), hypersensitivity pneumonitis (HP), or usual interstitial pneumonitis (UIP)/pulmonary fibrosis 2
  • Higher risk observed in patients with non-small cell lung cancer compared to melanoma patients 2

Hypersensitivity Pneumonitis

  • Caused by inhalation of various environmental antigens leading to an exaggerated immune response 2, 3
  • Common inciting agents include:
    • Organic dusts (moldy hay, straw) 3
    • Bird proteins (from pigeons, parakeets) 4
    • Contaminated humidifiers 4
    • Indoor molds 4
  • Characterized by CD4+ T cell differentiation into Th1 cells promoting granuloma formation 2
  • Can progress to irreversible fibrosis if exposure continues 3, 4

Drug-Induced Pneumonitis

  • Methotrexate can cause interstitial pneumonitis, alveolitis, and respiratory failure 5
  • Other medications associated with pneumonitis include:
    • Cancer drugs
    • Drugs for autoimmune diseases
    • Amiodarone
    • Antibiotics 1
  • Clinical presentation ranges from asymptomatic to life-threatening 1

Chemical Pneumonitis

  • Caused by inhalation of organic and nonorganic chemical agents 6
  • More soluble agents affect upper respiratory tract, while less soluble agents reach distal airways causing pulmonary edema 6
  • Can lead to long-term complications including bronchiectasis, bronchiolitis obliterans, and lung destruction 6

Viral Pneumonitis

  • Can affect all age groups and both immunocompetent and immunocompromised hosts 7
  • Common viral causes include:
    • Respiratory syncytial virus
    • Adenoviruses
    • Varicella-zoster virus
    • Herpes simplex virus
    • Influenza A and B viruses
    • Cytomegalovirus 7

Sarcoidosis and Sarcoid-like Reactions

  • Pulmonary sarcoidosis and sarcoid-like granulomatous reactions can occur following immune checkpoint inhibitor therapy 2
  • Characterized by increased numbers of T helper 17 (Th17.1) cells in bronchoalveolar lavage fluid 2
  • May present with cough, wheezing, fatigue and/or chest pain 2

Diagnostic Considerations

  • Bronchoalveolar lavage (BAL) cellular analysis can help differentiate between causes of pneumonitis 2
  • BAL cell differential counts with >15% lymphocytes, >3% neutrophils, >1% eosinophils, and >0.5% mast cells represent different cellular patterns with diagnostic implications 2
  • High-resolution CT is essential for diagnosis and should be performed as early as possible when pneumonitis is suspected 1
  • Pneumonitis must be distinguished from pneumonia, diffuse alveolar hemorrhage, pulmonary edema, radiation pneumonitis, and pulmonary metastases 1

Clinical Implications and Management

  • If unchecked, pneumonitis can lead to pulmonary fibrosis, respiratory insufficiency, and even death 1, 3
  • Primary approach is to identify and remove the causative agent 1
  • For immune checkpoint inhibitor-related pneumonitis, treatment is based on severity grading, with drug withdrawal as the mainstay for all grades 2
  • Corticosteroids are indicated for moderate to severe cases, with additional immunosuppression (infliximab, cyclophosphamide) for recalcitrant disease 2

Early recognition and treatment are essential to prevent progression to chronic, irreversible disease 1.

References

Guideline

Pneumonitis: Definition, Clinical Understanding, and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Hypersensitivity pneumonitis.

Allergy, 2009

Research

Hypersensitivity pneumonitis: current concepts and future questions.

The Journal of allergy and clinical immunology, 2001

Research

Chemical pneumonitis.

Radiologic clinics of North America, 1992

Research

Viral pneumonitis.

Clinics in chest medicine, 1991

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.